Rosacea
Conditions
Keywords
Rosacea, Dermatology, UCSD, Skin disease
Brief summary
The purpose of this study is to determine the effect of topical aminocaproic acid on the immune system by assessing the levels of antimicrobial peptides in the skin of patients with rosacea. It is hypothesized that aminocaproic acid applied topically will alter the body's immune system in patients with rosacea by inhibiting activation of antimicrobial peptides.
Interventions
DRUGTopical aminocaproic acid (ACA) mixed with Vanicream
25% Aminocaproic acid cream twice daily for up to 12 weeks.
DRUGVehicle cream
Vehicle cream moisturizer twice daily for up to 12 weeks
Sponsors
University of California, San Diego
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Subject is male or non-pregnant female, 18 - 70 years of age. * Subjects willing and able to give informed consent. * Subjects willing and able to comply with the requirements of the study. * Subject has the clinical diagnosis of at least mild/moderate papulopustular rosacea (3-20 papulopustules) and at least mild erythema. * Subject has been on a stable dose for greater than 3 months of medications for treatment of concurrent medical condition (including oral contraceptive pills, vasodilators, adrenergic blocking agents) OR the investigator has determined that the medications are unlikely to affect the patient's rosacea and/or treatment during the study * Subject is in general good health in the opinion of the investigator. * Subject has a calculated creatinine clearance 100% of normal range. * Subject has normal baseline labs or in the opinion of the investigator are values are not clinically significant and would not inhibit the ability to monitor the patient for both safety and efficacy throughout the study.
Exclusion criteria
* Subject has a diagnosis of Steroid Rosacea or Pyoderma Faciale (rosacea fulminans) * Subject has a history of Carcinoid, Pheochromocytoma, Serotonin Syndrome or other systemic flushing causes. * Subject has used facial topical therapies (OTC drug products or prescription products) for any reason within the prior 28 days * Subject has used systemic corticosteroid or systemic antibiotics (especially doxycycline, minocycline, tetracycline, metronidazole) within the prior 28 days. * Subject has had laser or light-based treatment for rosacea within the prior 3 months. * Subject has had systemic retinoids and retinoid derivatives over the past 6 months * Subject has an active or recent history of any coagulation (hyper or hypo) disorder, genitourinary bleeding, myopathy, cardiomyopathy, rhabdomyolysis or evidence of clinically significant hepatic disease in the opinion of the investigator, * Subject is taking any medicines or supplements that interfere with blood clotting such as Coumadin, Plavix, or ASA (\>81mg/day). * Subject has a known hypersensitivity or allergy to aminocaproic acid or components of the vehicle. * Subject is pregnant or lactating or planning a pregnancy during the duration of the study * Subject has been treated with another investigational device or drug within 28 days prior to study enrollment or intends to participate in a clinical trial concurrent with this study * Subject has clinically significant findings, medical history or conditions (other than rosacea), which in the opinion of the Investigator may compromise the study, treatment protocol, or safety of the patient or treatment allocation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Kallikrein 5 (KLK5) Protease Activity | Up to 12 weeks | Serine protease activity of KLK5 in adult skin from patients with rosacea is measured after treatment with vehicle or aminocaproic acid cream. Protease activity of facial skin surface is monitored using a synthetic fluorogenic trypsin-like proteinase substrate. Protease activity is monitored as an increase of fluorescence (RFU/uL) with SpectraMax GEMINI EM. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Aminocaproic Acid (ACA) Subjects will treat their facial skin twice daily for up to 12 weeks with 5-6 visits and 2 telephone visits. Investigator and subject will be blinded. Tape strip samples will be collected from facial skin at each visit to assess KLK activity and LL-37 expression.
Topical aminocaproic acid (ACA) mixed with Vanicream: 25% Aminocaproic acid cream twice daily for up to 12 weeks. | 11 |
| Vehicle Cream Subjects will apply vehicle twice daily for up to 12 weeks with 5-6 visits and 2 telephone visits. Investigator and subject will be blinded. Tape strip samples will be collected from facial skin at each visit to assess KLK activity and LL-37 expression.
Vehicle cream: Vehicle cream moisturizer twice daily for up to 12 weeks | 4 |
| Total | 15 |
Baseline characteristics
| Characteristic | Aminocaproic Acid (ACA) | Vehicle Cream | Total |
|---|---|---|---|
| Age, Continuous | 53 years STANDARD_DEVIATION 18.5 | 63 years STANDARD_DEVIATION 5.6 | 55.7 years STANDARD_DEVIATION 16.5 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 2 Participants | 1 Participants | 3 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 6 Participants | 2 Participants | 8 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 3 Participants | 1 Participants | 4 Participants |
| Sex: Female, Male Female | 7 Participants | 3 Participants | 10 Participants |
| Sex: Female, Male Male | 4 Participants | 1 Participants | 5 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 11 | 0 / 4 |
| other Total, other adverse events | 0 / 11 | 0 / 4 |
| serious Total, serious adverse events | 0 / 11 | 0 / 4 |
Outcome results
Primary
Kallikrein 5 (KLK5) Protease Activity
Serine protease activity of KLK5 in adult skin from patients with rosacea is measured after treatment with vehicle or aminocaproic acid cream. Protease activity of facial skin surface is monitored using a synthetic fluorogenic trypsin-like proteinase substrate. Protease activity is monitored as an increase of fluorescence (RFU/uL) with SpectraMax GEMINI EM.
Time frame: Up to 12 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Aminocaproic Acid (ACA) | Kallikrein 5 (KLK5) Protease Activity | 581.1 RFU/uL | Standard Deviation 261 |
| Vehicle Cream | Kallikrein 5 (KLK5) Protease Activity | 816.5 RFU/uL | Standard Deviation 422.4 |